Merck (MRK) director Glocer granted 405 phantom stock units, holds 5,100 shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
GLOCER THOMAS H reported acquisition or exercise transactions in this Form 4 filing.
Merck & Co., Inc. director Thomas H. Glocer received a grant of 405.2706 phantom stock units on March 31, 2026, credited at $120.29 per unit on a 1-for-1 basis with common stock. These phantom units are payable 100% in cash after his board service ends under the deferred compensation plan. He also reports direct ownership of 5,100 shares of Merck common stock, including shares accumulated through dividend reinvestment.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
GLOCER THOMAS H
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Phantom Stock | 405.271 | $120.29 | $49K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Phantom Stock — 108,293.493 shares (Direct);
Common Stock — 5,100 shares (Direct)
Footnotes (1)
- 1-for-1 Phantom stock units are to be settled 100% in cash upon reporting person's termination of service in accordance with a distribution schedule elected pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation. Holdings include shares acquired in dividend reinvestment transactions.
Key Figures
Phantom stock grant: 405.2706 units at $120.29
Total phantom stock units: 108,293.493 units
Direct common stock holdings: 5,100 shares
3 metrics
Phantom stock grant
405.2706 units at $120.29
Grant to director on March 31, 2026
Total phantom stock units
108,293.493 units
Phantom stock holdings after grant
Direct common stock holdings
5,100 shares
Common stock directly owned after reported date
Key Terms
Phantom stock, Plan for Deferred Payment of Directors' Compensation, dividend reinvestment transactions
3 terms
Phantom stock financial
"Phantom stock units are to be settled 100% in cash upon reporting person's termination of service"
A phantom stock is a form of compensation that gives employees or executives the benefits of stock ownership, such as the increase in stock value, without actually giving them real shares. It acts like a promise to pay the employee the equivalent value of company stock later, often as a bonus or incentive. This allows companies to motivate and reward staff without diluting ownership or transferring actual shares.
Plan for Deferred Payment of Directors' Compensation financial
"pursuant to the terms of the Plan for Deferred Payment of Directors' Compensation"
dividend reinvestment transactions financial
"Holdings include shares acquired in dividend reinvestment transactions"
FAQ
What did Merck (MRK) director Thomas H. Glocer report in this Form 4?
He reported receiving 405.2706 phantom stock units credited at $120.29 per unit on March 31, 2026. He also reported holding 5,100 shares of Merck common stock directly, including shares accumulated through dividend reinvestment transactions over time.
Is the Merck (MRK) Form 4 transaction a stock purchase or sale?
The filing shows an acquisition through a grant, not an open-market trade. Glocer received 405.2706 phantom stock units as a compensation-related award, with no reported buy or sell of Merck common stock in the transaction section of this Form 4.
How many phantom stock units does Thomas H. Glocer hold after this Merck (MRK) grant?
After the March 31, 2026 grant, Glocer holds a total of 108,293.493 phantom stock units. These units track Merck’s common stock on a 1-for-1 basis and are designed to be settled entirely in cash after his service on the board ends.
How are Merck (MRK) phantom stock units for directors settled?
The phantom stock units are settled 100% in cash upon the director’s termination of service. Payment follows a distribution schedule elected under Merck’s Plan for Deferred Payment of Directors’ Compensation, rather than being settled in actual Merck common shares.
What direct Merck (MRK) common stock holdings does Glocer report?
He reports direct ownership of 5,100 Merck common shares following the reported date. According to the disclosure, these direct holdings include shares that were acquired through dividend reinvestment transactions, adding to his position over time without separate open-market purchases.